inv(2)(p21p23) EML4::ALK
Oncogenic mechanisms
constitutively activivation of ALK kinase domain
Targeted therapy
Crizotinib
Alectinib
Ceritinib
Brigatinib
Lorlatinib
Tumor type
Follicular lymphoma
Diffuse large B-cell lymphoma
Lung adenocarcinoma
Non-small cell lung adenocarcinoma
Thyroid carcinoma
Highly cited references
| Pubmed ID | Year | Title | Citations |
|---|---|---|---|
| 23708071 | 2013 | Membrane phospholipids, EML4-ALK, and Hsp90 as novel targets in lung cancer treatment. | 135 |
| 35884511 | 2022 | Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer. | 134 |
| 26755435 | 2016 | Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs. | 116 |
| 37149843 | 2023 | EML4-ALK biology and drug resistance in non-small cell lung cancer: a new phase of discoveries. | 100 |
| 38284990 | 2024 | EML4-ALK fusions drive lung adeno-to-squamous transition through JAK-STAT activation. | 96 |
| 35928804 | 2022 | EML4-ALK fusion gene in non-small cell lung cancer. | 94 |
| 39488530 | 2024 | Oncogenic EML4-ALK assemblies suppress growth factor perception and modulate drug tolerance. | 88 |
| 37940761 | 2024 | EML4-ALK fusion protein in Lung cancer cells enhances venous thrombogenicity through the pERK1/2-AP-1-tissue factor axis. | 87 |
| 36982897 | 2023 | Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs. | 85 |
| 33878728 | 2021 | Targeting EML4-ALK gene fusion variant 3 in thyroid cancer. | 77 |
| 25806224 | 2013 | Targeting EML4-ALK driven non-small cell lung cancer (NSCLC). | 71 |
| 19032370 | 2008 | Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer. | 71 |
| 35806325 | 2022 | The Change in Paradigm for NSCLC Patients with EML4-ALK Translocation. | 62 |
| 33761896 | 2021 | EML4-ALK induces cellular senescence in mortal normal human cells and promotes anchorage-independent growth in hTERT-transduced normal human cells. | 58 |
| 32184261 | 2020 | EML4-ALK V3 oncogenic fusion proteins promote microtubule stabilization and accelerated migration through NEK9 and NEK7. | 58 |
| 28938691 | 2017 | Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. | 58 |
| 38023218 | 2023 | Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review. | 57 |
| 33907223 | 2021 | ALK inhibition activates LC3B-independent, protective autophagy in EML4-ALK positive lung cancer cells. | 50 |
| 38264745 | 2023 | ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinib. | 47 |
| 28872581 | 2017 | EML4-ALK Variants: Biological and Molecular Properties, and the Implications for Patients. | 45 |
| 34661367 | 2021 | Phase-separated foci of EML4-ALK facilitate signalling and depend upon an active kinase conformation. | 43 |
| 20418096 | 2010 | The biology and treatment of EML4-ALK non-small cell lung cancer. | 43 |
| 25971657 | 2015 | The EML4-ALK oncogene: targeting an essential growth driver in human cancer. | 42 |
| 26301689 | 2015 | RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. | 42 |
| 32047559 | 2020 | Comparison of EML4-ALK fusion gene positive rate in different detection methods and samples of non-small cell lung cancer. | 42 |
| 28370702 | 2017 | Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells. | 42 |
| 38360931 | 2024 | Inflammation-related molecular signatures involved in the anticancer activities of brigatinib as well as the prognosis of EML4-ALK lung adenocarcinoma patient. | 41 |
| 25727400 | 2015 | Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. | 41 |
| 35656694 | 2022 | EML4-ALK Variant 3 Promotes Mitotic Errors and Spindle Assembly Checkpoint Deficiency Leading to Increased Microtubule Poison Sensitivity. | 39 |
| 27141364 | 2016 | EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3. | 39 |
| 32558295 | 2020 | Vulnerability of drug-resistant EML4-ALK rearranged lung cancer to transcriptional inhibition. | 38 |
| 29774063 | 2018 | Dual target gene therapy to EML4-ALK NSCLC by a gold nanoshell-based system. | 38 |
| 38205204 | 2023 | Efficacy of alectinib in lung adenocarcinoma patients with different anaplastic lymphoma kinase (ALK) rearrangements and co-existing alterations-a retrospective cohort study. | 38 |
| 38433979 | 2024 | Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. | 36 |
| 19667260 | 2009 | EML4-ALK: honing in on a new target in non-small-cell lung cancer. | 35 |
| 33976114 | 2021 | Phase separation of EML4-ALK in firing downstream signaling and promoting lung tumorigenesis. | 34 |
| 27078848 | 2016 | CRKL mediates EML4-ALK signaling and is a potential therapeutic target for ALK-rearranged lung adenocarcinoma. | 34 |
| 25806283 | 2014 | Concordance of IHC, FISH and RT-PCR for EML4-ALK rearrangements. | 33 |
| 29054983 | 2018 | ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms. | 33 |
| 36325153 | 2022 | Potential Therapeutic Strategy for EGFR-Mutant Lung Cancer With Concomitant EML4-ALK Rearrangement-Combination of EGFR Tyrosine Kinase Inhibitors and ALK Inhibitors. | 33 |
| 25407901 | 2014 | Non-small cell lung cancer with EML4-ALK translocation in Chinese male never-smokers is characterized with early-onset. | 33 |
| 38448512 | 2024 | New pan-ALK inhibitor-resistant EML4::ALK mutations detected by liquid biopsy in lung cancer patients. | 32 |
| 35159046 | 2022 | A Polytherapy Strategy Using Vincristine and ALK Inhibitors to Sensitise EML4-ALK-Positive NSCLC. | 32 |
| 33425389 | 2020 | The Prevalence of the EML4-ALK Fusion Gene in Cytology Specimens from Patients with Lung Adenocarcinoma. | 32 |
| 18594010 | 2008 | EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. | 31 |
| 35144623 | 2022 | Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity to crizotinib in two lung adenocarcinoma patients, respectively. | 31 |
| 34090412 | 2021 | EML4-ALK-mediated activation of the JAK2-STAT pathway is critical for non-small cell lung cancer transformation. | 29 |
| 30679319 | 2019 | Carcinoma of Unknown Primary with EML4-ALK Fusion Response to ALK Inhibitors. | 27 |
| 39522087 | 2024 | A novel double fusion of EML4-ALK and PLEKHA7-ALK contribute to rapid progression of lung adenocarcinoma: a case report and literature review. | 23 |
| 20075203 | 2010 | EML4-ALK fusion in lung. | 19 |
| 37007089 | 2023 | Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report. | 19 |
| 36221356 | 2022 | Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib. | 19 |
| 37055606 | 2023 | Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report. | 18 |
| 29952952 | 2018 | Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma. | 18 |
| 39840587 | 2025 | Impact of EML4-ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non-small Cell Lung Cancer. | 17 |
| 22323876 | 2012 | EML4-ALK fusion gene in Korean non-small cell lung cancer. | 16 |
| 30631567 | 2018 | Examining EML4-ALK variants in the clinical setting: the next frontier? | 15 |
| 30023099 | 2018 | EML4-ALK V3, treatment resistance, and survival: refining the diagnosis of ALK(+) NSCLC. | 12 |
| 32212216 | 2020 | Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report. | 12 |
| 37510070 | 2023 | EML4-ALK Gene Mutation Detected with New NGS Lung Cancer Panel CDx Using Sputum Cytology in a Case of Advanced NSCLC. | 11 |
| 18320074 | 2008 | EML4-ALK fusion lung cancer: a rare acquired event. | 10 |
| 30068733 | 2018 | Endometrial cancer with an EML4-ALK rearrangement. | 7 |
| 35117067 | 2019 | EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy. | 5 |
| 30902613 | 2019 | Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. | 0 |
| 34175504 | 2021 | Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC. | 0 |
| 37541389 | 2023 | Efficacy of Lorlatinib in Treatment-Naive Patients With ALK-Positive Advanced NSCLC in Relation to EML4::ALK Variant Type and ALK With or Without TP53 Mutations. | 0 |
| 30069772 | 2018 | Alectinib. | 0 |
| 37377128 | 2023 | EML4::ALK fusions in complex lymphatic malformations. | 0 |
| 29494260 | 2018 | EML4-ALK Variant Affects ALK Resistance Mutations. | 0 |
| 27458283 | 2016 | Differential Sensitivity to Crizotinib: Does EML4-ALK Fusion Variant Matter? | 0 |
| 39019326 | 2024 | Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM database. | 0 |
| 39510702 | 2024 | EML4-ALK Variants and Co-Occurring TP53 Mutations in a Real-World Treatment Setting: Do They Matter? | 0 |
| 35085771 | 2022 | EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3/Slug signaling. | 0 |
| 31432686 | 2019 | The prevalence of EML4-ALK variants in patients with non-small-cell lung cancer: a systematic review and meta-analysis. | 0 |
| 34233240 | 2021 | Concomitance of a novel RMDN2-ALK fusion and an EML4-ALK fusion in a lung adenocarcinoma. | 0 |
| 35074224 | 2022 | Targeting Alternative Splicing as Adjunctive Treatment in EML4-ALK v3a/b+ NSCLC: Knowing Our Socratic Paradox and Learning From Spinal Muscular Atrophy. | 0 |
| 34763158 | 2021 | Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report. | 0 |
| 35933914 | 2022 | Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLC. | 0 |
| 30791979 | 2019 | miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC. | 0 |
| 32878782 | 2020 | ALK Inhibitors Do Not Increase Sensitivity to Radiation in EML4-ALK Non-small Cell Lung Cancer. | 0 |
| 32409002 | 2020 | A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib. | 0 |
| 39318039 | 2025 | EML4-ALK G1202R and EML4-ALK L1196M mutations induce crizotinib resistance in non-small cell lung cancer cells through activating epithelial-mesenchymal transition mediated by MDM2/MEK/ERK signal axis. | 0 |
| 22912387 | 2012 | Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. | 0 |
| 34391065 | 2021 | Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance. | 0 |
| 31711728 | 2020 | Identification of EML4-ALK fusion in a sporadic case of cholangiocarcinoma. | 0 |
| 34378283 | 2021 | An unusual fusion gene EML4-ALK in a patient with congenital mesoblastic nephroma. | 0 |
| 18242762 | 2008 | EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. | 0 |
| 39078281 | 2024 | SIRT1 silencing promotes EMT and Crizotinib resistance by regulating autophagy through AMPK/mTOR/S6K signaling pathway in EML4-ALK L1196M and EML4-ALK G1202R mutant non-small cell lung cancer cells. | 0 |
| 33017727 | 2020 | Distribution of EML4-ALK fusion variants and clinical outcomes in patients with resected non-small cell lung cancer. | 0 |
| 25735977 | 2015 | EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells. | 0 |
| 21102254 | 2010 | EML4/ALK and ras inhibitors. | 0 |
| 21569690 | 2011 | [EML4-ALK fusion in non-small-cell lung cancer]. | 0 |
| 18166835 | 2008 | EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers. | 0 |
| 22706607 | 2012 | A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK. | 0 |
| 39253447 | 2024 | Cancer-associated fibroblasts confer ALK inhibitor resistance in EML4-ALK -driven lung cancer via concurrent integrin and MET signaling. | 0 |
| 26781614 | 2016 | ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern. | 0 |
| 22964709 | 2012 | EML4-ALK rearrangement and its clinical significance in Chinese patients with advanced non-small cell lung cancer. | 0 |
| 38097451 | 2024 | Localised ALK-positive histiocytosis in lung with EML4::ALK fusion. | 0 |
| 25144242 | 2014 | A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell line. | 0 |
| 24891363 | 2014 | EML4-ALK fusions: propelling cancer but creating exploitable chaperone dependence. | 0 |
Bibliography
| Pubmed ID | Publication Year | Title | Authors |
|---|---|---|---|
| 21645460 | 2011 | [A new target in non-small cell lung cancer: EML4-ALK fusion gene]. | Wang H, et al |
| 20418096 | 2010 | The biology and treatment of EML4-ALK non-small cell lung cancer. | Sasaki T, et al |
| 19734424 | 2009 | The EML4-ALK transcript but not the fusion protein can be expressed in reactive and neoplastic lymphoid tissues. | Sozzi G, et al |
